OncoMatch/Clinical Trials/NCT05038332
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
Is NCT05038332 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for prostate cancer.
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy \[SBRT\]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Demographics
Prior therapy
Must have received: radical prostatectomy
histologically confirmed prostate cancer after radical prostatectomy
Cannot have received: pelvic radiation therapy
Prior history of pelvic radiation therapy
Cannot have received: androgen deprivation therapy
Exception: LHRH / GnRH agonist or antagonist allowed if initiated ≤ 6 months prior to enrollment
Initiation of androgen deprivation therapy with a LHRH / GnRH agonist or antagonist greater than 6 months prior to enrollment or receipt of any non-LHRH / GnRH agonist or antagonist androgen deprivation or anti-androgen therapy
Cannot have received: anti-androgen therapy
receipt of any non-LHRH / GnRH agonist or antagonist androgen deprivation or anti-androgen therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Michigan Rogel Cancer Center · Ann Arbor, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05038332 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior pelvic radiation therapy, androgen deprivation therapy, anti-androgen therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages